Urinary matrix metalloproteinases and their endogenous inhibitors predict hepatic regeneration after murine partial hepatectomy

Transplantation

Volumn 78, Issue 8, 2004, Pages 1139-1144

  Greene, Arin K ^a   Puder, Mark ^a   Roy, Roopali ^a   Kilroy, Susan ^a   Louis, Gwendolyn ^a   Folkman, Judah ^a   Moses, Marsha A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Liver regeneration; Matrix metalloproteinase; TIMP; TNP 470

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GEL ELECTROPHORESIS; LIVER REGENERATION; LIVER TRANSPLANTATION; MALE; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; URINE LEVEL; WESTERN BLOTTING; ZYMOGRAPHY;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CYCLOHEXANES; ELECTROPHORESIS; HEPATECTOMY; LIVER REGENERATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; SESQUITERPENES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 7044220262     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000137935.81103.A2     Document Type: Article

References (33)

1. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999; 19: 1589.
2. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248: 1408.
3. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157: 351.
4. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997; 15: 180.
5. Folkman J. Angiogenesis. In: Braunwald E, Fauci AS, Isselbacher KJ, et al., eds. Harrison's textbook of internal medicine. New York: McGraw Hill 2001, p. 517.
6. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52: 4548.
7. Nakajima M, Welch DR, Wynn DM, et al. Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 1993; 53: 5802.
8. Zucker S, Lysik RM, Zarrabi MH, et al. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993; 53: 140.
9. Zucker S, Lysik RM, Zarrabi HM, et al. Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Ann N Y Acad Sci 1994; 732: 248.
10. Gohji K, Fujimoto N, Fujii A, et al. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 1996; 56: 3196.
11. Moses MA, Wiederschain D, Loughlin KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58: 1395.
12. Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001; 61: 2207
13. Higgins GK, Johnson D Jr. Detection of antihypertensive agents in urine. Trans Assoc Life Insur Med Dir Am 1964; 48: 186.
14. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276: 60.
15. Greene AK, Wiener S, Puder M, et al. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg 2003; 237: 530.
16. Haruyama T, Ajioka I, Akaike T, et al. Regulation and significance of hepatocyte-derived matrix metalloproteinases in liver remodeling. Biochem Biophys Res Commun 2000; 272: 681.
17. Kim TH, Mars WM, Stolz DB, et al. Expression and activation of pro-MMP-2 and pro-MMP-9 during rat liver regeneration. Hepatology 2000; 31: 75.
18. Rudolph KL, Trautwein C, Kubicka S, et al. Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats. Hepatology 1999; 30: 1159.
19. Greene AK, Puder M. Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg 2003; 16: 99.
20. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555.
21. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69: 212.
22. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004; 10: 255.
23. Moses MA, Shing Y. Production of matrix metalloproteinases and a metalloproteinase inhibitor by swarm rat chondrosarcoma. Biochem Biophys Res Commun 1994; 199: 418.
24. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999; 99: 1726.
25. Zucker S, Eckhardt SG, Rowinsky EK. Plasma MMPs as surrogates of BAY 12-9566. J Clin Oncol 2000; 18: 1805.
26. Lein M, Nowak L, Jung K, et al. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997; 30: 491.
27. Jung K, Lein M, Laube C, et al. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001; 314: 241.
28. Stricklin GP. Human fibroblast tissue inhibitor of metalloproteinases: glycosylation and function. Coll Relat Res 1986; 6: 219.
29. Knittel T, Mehde M, Grundmann A, et al. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol 2000; 113: 443.
30. Yan L, Moses MA. A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma. Am J Pathol 2001; 158: 1185.
31. Lim MS, Guedez L, Stetler-Stevenson WG, et al. Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes. Ann N Y Acad Sci 1999; 878: 522.
32. Bloomston M, Shafii A, Zervos EE, et al. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 2002; 102: 39.
33. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993; 156: 235.